ZA200706394B - Fused aromatic compounds having anti-diabetic activity - Google Patents

Fused aromatic compounds having anti-diabetic activity

Info

Publication number
ZA200706394B
ZA200706394B ZA200706394A ZA200706394A ZA200706394B ZA 200706394 B ZA200706394 B ZA 200706394B ZA 200706394 A ZA200706394 A ZA 200706394A ZA 200706394 A ZA200706394 A ZA 200706394A ZA 200706394 B ZA200706394 B ZA 200706394B
Authority
ZA
South Africa
Prior art keywords
aromatic compounds
fused aromatic
diabetic activity
diabetic
activity
Prior art date
Application number
ZA200706394A
Other languages
English (en)
Inventor
Harold B Wood
Peter T Meinke
Guo Q Shi
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ZA200706394B publication Critical patent/ZA200706394B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
ZA200706394A 2005-03-04 2007-08-01 Fused aromatic compounds having anti-diabetic activity ZA200706394B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65866105P 2005-03-04 2005-03-04

Publications (1)

Publication Number Publication Date
ZA200706394B true ZA200706394B (en) 2008-09-25

Family

ID=36615702

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200706394A ZA200706394B (en) 2005-03-04 2007-08-01 Fused aromatic compounds having anti-diabetic activity

Country Status (18)

Country Link
US (1) US7834036B2 (ko)
EP (1) EP1861382B1 (ko)
JP (1) JP4638512B2 (ko)
KR (1) KR20070110324A (ko)
CN (2) CN102584754B (ko)
AU (1) AU2006220809B2 (ko)
BR (1) BRPI0609352A2 (ko)
CA (1) CA2598725C (ko)
CR (1) CR9401A (ko)
ES (1) ES2393793T3 (ko)
IL (1) IL185394A0 (ko)
MA (1) MA29352B1 (ko)
MX (1) MX2007010745A (ko)
NI (1) NI200700200A (ko)
NO (1) NO20075000L (ko)
RU (1) RU2007136784A (ko)
WO (1) WO2006096564A1 (ko)
ZA (1) ZA200706394B (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1993543A2 (en) * 2006-03-03 2008-11-26 Merck & Co., Inc. Novel crystalline forms of antidiabetic compounds
WO2008109334A1 (en) 2007-03-02 2008-09-12 Merck & Co., Inc. Novel crystalline salt form of an antidiabetic compound
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
CA2688187C (en) * 2007-05-07 2016-10-11 Merck & Co., Inc. Method of treament using fused aromatic compounds having anti-diabetic activity
US20120035105A1 (en) * 2009-01-09 2012-02-09 Sdg, Inc. Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
WO2014134776A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN104725219B (zh) * 2015-02-11 2017-08-08 华中农业大学 S‑2‑(4‑甲氧基苯氧基)丙酸钠的制备方法
AR110038A1 (es) 2016-05-26 2019-02-20 Kalyra Pharmaceuticals Inc Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos
EP3740206B1 (en) 2018-01-16 2024-03-06 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2019209470A1 (en) 2018-01-16 2020-08-13 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
JP2022515705A (ja) 2018-11-01 2022-02-22 サイロス ファーマシューティカルズ, インコーポレイテッド サイクリン依存性キナーゼ7(cdk7)の非共有結合性阻害剤を用いてバイオマーカーにより特定された患者におけるがんを処置する方法
US20240109865A1 (en) 2020-12-30 2024-04-04 Tyra Biosciences, Inc. Indazole compounds as kinase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525217A (ja) 1999-10-22 2003-08-26 メルク エンド カムパニー インコーポレーテッド 肥満治療用薬剤
AU784722B2 (en) * 2000-02-18 2006-06-01 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
JP2001354671A (ja) * 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤応答性受容体δの活性化剤
ATE362468T1 (de) 2000-07-25 2007-06-15 Merck & Co Inc N-substituierte indole mit anwendung in der behandlung von diabetes
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
AU2002251978B2 (en) 2001-02-09 2007-07-19 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
JP4542757B2 (ja) * 2002-08-08 2010-09-15 武田薬品工業株式会社 縮合複素環化合物
EP1527049B8 (en) 2002-08-08 2008-10-29 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as peptidase inhibitors
CN100457730C (zh) 2002-08-29 2009-02-04 默克公司 具有抗糖尿病活性的吲哚化合物
US7393960B2 (en) * 2002-08-29 2008-07-01 Merck & Co., Inc. Indoles having anti-diabetic activity
ATE488236T1 (de) * 2004-09-16 2010-12-15 Merck Sharp & Dohme Verbindungen zur behandlung von dyslipidämie und anderer lipidstörungen

Also Published As

Publication number Publication date
EP1861382A1 (en) 2007-12-05
JP2008531729A (ja) 2008-08-14
MA29352B1 (fr) 2008-03-03
AU2006220809B2 (en) 2009-06-11
JP4638512B2 (ja) 2011-02-23
CA2598725A1 (en) 2006-09-14
RU2007136784A (ru) 2009-04-10
CA2598725C (en) 2010-10-26
IL185394A0 (en) 2008-02-09
KR20070110324A (ko) 2007-11-16
US7834036B2 (en) 2010-11-16
CN102584754B (zh) 2016-02-03
WO2006096564A1 (en) 2006-09-14
EP1861382B1 (en) 2012-10-10
CN102584754A (zh) 2012-07-18
NO20075000L (no) 2007-11-30
MX2007010745A (es) 2007-09-12
AU2006220809A1 (en) 2006-09-14
CN101128441A (zh) 2008-02-20
US20080194586A1 (en) 2008-08-14
CR9401A (es) 2008-02-21
ES2393793T3 (es) 2012-12-28
BRPI0609352A2 (pt) 2011-10-18
NI200700200A (es) 2008-02-29

Similar Documents

Publication Publication Date Title
ZA200706394B (en) Fused aromatic compounds having anti-diabetic activity
IL192395A0 (en) Modified lysine-mimetic compounds
IL189775A0 (en) Ppar active compounds
IL189776A0 (en) Ppar active compounds
GB0521244D0 (en) Benzamide compounds
GB0502316D0 (en) Compounds
EP1961741A4 (en) M-CARBAZOLYLPHENYL COMPOUNDS
HU0500920D0 (en) New compounds
GB0502310D0 (en) Compounds
HU0500921D0 (en) New compounds
EP1934217A4 (en) NEW COMPOUNDS II
AP2007004220A0 (en) Motilide compounds
EP1907385A4 (en) LINKS
HU0501170D0 (en) New compounds
HU0501168D0 (en) New compounds
HU0500886D0 (en) New compounds
HU0500879D0 (en) New compounds
HU0500877D0 (en) New compounds
GB0501985D0 (en) Compounds
EP1867650A4 (en) HYDROXYMETHYLBORVERBINDUNGEN
GB0501984D0 (en) Compounds
HU0501166D0 (en) New compounds
HU0500878D0 (en) New compounds
GB0506165D0 (en) Benzamide compounds
GB0513999D0 (en) Benzamide compounds